News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Shanghai Duyiwei Biotech Strikes mAb Deal With Apexigen


3/6/2012 11:54:38 AM

March 6, 2012 -- Shanghai Duyiwei Biotechnology, a subsidiary of Gansu Duyiwei Biological Pharma, announced an agreement with California-based Apexigen to develop monoclonal antibody drugs to treat cancer. Shanghai Duyiwei is paying $13.8 million to help underwrite Apexigen’s drug development costs. Apexigen previously established collaborations with Simcere Pharma and 3SBio. More details....

Stock Symbols: (SHE: 002219) (NYSE: SCR) (NSDQ: SSRX)


Read at ChinaBio Today


comments powered by Disqus
Apexigen
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES